NMD4C Members Presenting at Cure SMA Canada’s Winter Conference
About this Event, hosted by Cure SMA Canada
Thursday December 10 – Sunday December 13, 2020
Welcome to the Cure SMA Canada national SMA conference!
Cure SMA Canada are excited to be able to provide engaging, diverse, and informative topics for Canada’s SMA community to learn, heal and grow. Together we create an amazing cohesive community, learning from each other and making every tomorrow better than today.
Cure SMA would like to thank their sponsors, presenters and attendees.
NMD4C Presenters:
The NMD4C is excited to see many of its members present at this conference!
- Mise à jour sur le Risdiplam. Dr. Maryam Oskoui
- Nusinersen treatment update for adults with SMA. Dr. Erin K. O’Ferrall
- Care for the Caregiver. Rhonda Teichrob
- Spinraza – mise à jour pédiatrique. Dr. Nicolas Chrestian
- Pediatric update on Spinraza. Dr. Hernan Gonorazky
- Risdiplam update. Dr. Maryam Oskoui
- Peripheral pathology in SMA: Implications for clinical care (What goes wrong in SMA and how to fix it – lessons learned from recent studies). Dr. Rashmi Kothary
- Biomarkers for SMA. Dr. Robin Parks
- À la recherche du role d’SMN dans les neurones et muscles : une stratégie pour l’identification de nouvelles cibles thérapeutiques pour l’Amyotrophie Spinale Infantile. Dr. Jocelyn Côté
- Teens/adult transition and the importance of multidisciplinary care. Dr. Aaron Izenberg
- The Changing Landscape of Respiratory Care for SMA. Dr. Reshma Amin
Click Here for the full Agenda
Register Now!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.